6633 results about "Phenyl group" patented technology

Processes for precursors for silicon dielectric depositions of silicon nitride, silicon oxide and silicon oxynitride on a substrate using a hydrazinosilane of the formula:

[R¹₂N—NH]_nSi(R²)_4−n

where each R¹ is independently selected from alkyl groups of C₁ to C₆; each R² is independently selected from the group consisting of hydrogen, alkyl, vinyl, allyl, and phenyl; and n=1–4. Some of the hydrazinosilanes are novel precursors.

A tire or tire tread incorporating an elastomeric composition having improved vulcanization kinetics, based on at least a diene elastomer, a reinforcing inorganic filler and, as (inorganic filler/elastomer) coupling agent, a bis-alkoxysilane tetrasulfide of the formula:

in which:

• • the symbols R¹, which may be identical or different, each represent a monovalent hydrocarbon group selected from among the group consisting of alkyls, whether straight-chain or branched, having from 1 to 4 carbon atoms, and alkoxyalkyls, whether straight-chain or branched, having from 2 to 8 carbon atoms;
  • R² and R³, which may be identical or different, each represent a monovalent hydrocarbon group selected from among the group consisting of alkyls, whether straight-chain or branched, having from 1 to 6 carbon atoms, and the phenyl radical; and
  • x is between about 3 and about 5.

A γ,δ-unsaturated carboxylic acid silyl ester is prepared by reacting an α,β-unsaturated carboxylic acid ester with a hydrosilane or hydrosiloxane in the presence of tris(pentafluorophenyl)borane. γ,δ-Unsaturated carboxylic acid derivatives are readily prepared through fewer steps and in high yields.

A method is provided for processing a substrate including providing a processing gas comprising an organosilicon compound comprising a phenyl group to the processing chamber, and reacting the processing gas to deposit a low k silicon carbide barrier layer useful as a barrier layer in damascene or dual damascene applications with low k dielectric materials. A method is provided for depositing a silicon carbide cap layer that has substantially no phenyl groups attached to silicon atoms from a processing gas comprising an oxygen-free organosilicon compound on a low k silicon carbide barrier layer.

A metal coordination compound suitable as an organic material for a luminescent device is represented by the following formula (1): wherein M denotes Ir, Pt, Rh or Pd; n is 2 or 3; Y denotes an alkylene group having 2-6 carbon atoms capable of including one or at least two non-neighboring methylene groups which can be replaced with -O-, -S- or -CO- and capable of including hydrogen atom which can be replaced with a linear or branched alkyl group which has 1-10 carbon atoms and is capable of including hydrogen atom which can be replaced with fluorine atom; and CyN denotes a cyclic group containing nitrogen atom connected to M and capable of having a substituent selected from the group consisting of halogen atom; nitro group; phenyl group; trialkylsilyl group having 1-8 carbon atoms; and a linear or branched alkyl group having 1-20 carbon atoms capable of including one or at least two non-neighboring methylene groups which can be replaced with -O-, -S-, -CO-, -CO-O-, -O-CO-, -CH=CH- or -C=C- and capable of including hydrogen atom which can be replaced with fluorine atom.

The present invention relates to a compound represented by Formula (I):

(wherein Ar₁ represents an imidazolyl group which may be substituted with 1 to 3 substituents; Ar₂ represents a pyridinyl group, a pyrimidinyl group, or a phenyl group which may be substituted with 1 to 3 substituents; X₁ represents (1) —C≡C— or (2) a double bond etc. which may be substituted; R¹ and R² represent, for example, a C1-6 alkyl group or C3-8 cycloalkyl group which may be substituted)

or a pharmacologically acceptable salt thereof and to the use thereof as pharmaceutical agents. The object of the present invention is to find a therapeutic or preventive agent for diseases caused by Aβ. According to the present invention, a therapeutic or preventive agents for diseases caused by Aβ can be provided.

A class of 2′-fluoro-nucleoside compounds are disclosed which are useful in the treatment of hepatitis B infection, hepatitis C infection, HIV and abnormal cellular proliferation, including tumors and cancer. The compounds have the general formulae:

wherein

• [0001]
  • Base is a purine or pyrimidine base;
  [0002]
  • R¹ is OH, H, OR³, N₃, CN, halogen, including F, or CF₃, lower alkyl, amino, loweralkylamino, di(lower)alkylamino, or alkoxy, and base refers to a purine or pyrimidine base;
  [0003]
  • R² is H, phosphate, including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug; acyl, or other pharmaceutically acceptable leaving group which when administered in vivo, is capable of providing a compound wherein R² is H or phosphate; sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl, benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given above, a lipid, an amino acid, peptide, or cholesterol; and
  [0004]
  • R³ is acyl, alkyl, phosphate, or other pharmaceutically acceptable leaving group which when administered in vivo, is capable of being cleaved to the parent compound, or a pharmaceutically acceptable salt thereof.

A method is provided for processing a substrate including providing a processing gas comprising hydrogen gas and an organosilicon compound comprising a phenyl group to the processing chamber, and reacting the processing gas to deposit a low k silicon carbide barrier layer useful as a barrier layer in damascene or dual damascene applications with low k dielectric materials.

Provided is a novel substance that can emit phosphorescence. Alternatively, provided is a novel substance with high emission efficiency. An organometallic complex in which a 4-arylpyrimidine derivative is a ligand and iridium is a central metal is provided. Specifically, an organometallic complex having a structure represented by a general formula (G1) is provided. In the general formula (G1), R¹ represents a substituted or unsubstituted alkyl group having 1 to 4 carbon atoms or a substituted or unsubstituted aryl group having 6 to 10 carbon atoms, R² represents any of hydrogen, a substituted or unsubstituted alkyl group having 1 to 4 carbon atoms, and a substituted or unsubstituted phenyl group, R³ represents hydrogen or a substituted or unsubstituted alkyl group having 1 to 4 carbon atoms, and Ar¹ represents a substituted or unsubstituted arylene group having 6 to 10 carbon atoms.

Panchromatic photosensitizers having a Formula of ML₁L₂X were synthesized, wherein M comprises ruthenium atom; X is a monodentate anion; L₁ is heterocyclic bidentate ligand having one of formulae listed below:

The substituents R₁, R₂, R₃, R₄, R₅, R₆, R₇ of L₁ and L₂ are the same or different, and represent alkyl, alkoxy, alkylthio, alkylamino, halogenated alkyl, phenyl or substituted phenyl group, carboxylic acid or counter anion thereof, sulfonic acid or counter anion thereof, phosphoric acid or counter anion thereof, amino-group, halogens, or hydrogen. The above-mentioned photosensitizers are suitable to use as sensitizers for fabrication of high efficiency dye-sensitized solar cell.

The light emitting device of the present invention relates to a light emitting device which is characterized in that it is a device with an emissive substance present between an anode and cathode, and which emits light by means of electrical energy, and said device has a least one type of compound denoted by (a) to (d) below. (a) A compound having a plurality of 1,7-phenanthroline skeletal structures (b) A benzoquinoline derivative (c) A spiro compound represented by general formula (1) A1 and A2 are each selected from single bonds, substituted or unsubstituted alkyl chains, ether chains, thioether chains, ketone chains and substituted or unsubstituted amino chains. However, A1<> A2. Z represents carbon or silicon. R1 to R16 are each selected from hydrogen, alkyl group, cycloalkyl group, aralkyl group, alkenyl group, cycloalkenyl group, alkynyl group, hydroxyl group, mercapto group, alkoxy group, alkylthio group, aryl ether group, aryl thioether group, aryl group, heterocyclic group, halogen, haloalkane, haloalkene, haloalkyne, cyano group, aldehyde group, carbonyl group, carboxyl group, ester group, carbamoyl group, amino group, nitro group, silyl group, siloxanyl group and a cyclic structure formed with an adjacent substituent. (d) A tetraphenylmethane derivative represented by general formula (2) R17 to R36 are each selected from hydrogen, alkyl group, cycloalkyl group, aralkyl group, alkenyl group, cycloalkenyl group, alkynyl group, hydroxyl group, mercapto group, alkoxy group, alkylthio group, aryl ether group, aryl thioether group, aryl group, heterocyclic group, halogen, haloalkane, haloalkene, haloalkyne, cyano group, aldehyde group, carbonyl group, carboxyl group, ester group, carbamoyl group, amino group, nitro group, silyl group, siloxanyl group and a cyclic structure formed with an adjacent substituent. However, at least one of R17 to R36 is selected from substituents represented by general formula (3). -X-Ar (3) X is a single bond or is selected from the following, and Ar denotes a condensed aromatic ring or heteroaromatic ring. In the case where X is phosphorus oxide, then Ar represents an aromatic hydrocarbon or heteroaromatic ring. n is an natural number.

The present invention relates to a novel two cyclic cinnamide compound and a pharmaceutical agent comprising the compound as an active ingredient. The two cyclic cinnamide compound represented by the general formula (I):

wherein represents a single bond or a double bond; Ar₁ represents a phenyl group or pyridinyl group that may be substituted with 1 to 3 substituents; R¹ and R² each represent a C1-6 alkyl group, a hydroxyl group, or the like; Z₁ represents a methylene group or vinylene group, which may be substituted with 1 or 2 substituents selected from Substituent Group A1, an oxygen atom, or an imino group that may be substituted with a substituent selected from Substituent Group A1; and p, q, and r each represent an integer of 0 to 2, which has an effect of reducing Aβ40 and Aβ42 production, and thus is particularly useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by Aβ such as Alzheimer's disease or Down's syndrome.

The present invention provides an organic electroluminescent element which is superior in luminance, reliability, and thermal stability and is capable of selectively emitting light with comparative long wavelengths such as red and good color purity and a light-emitting device or display device incorporated therewith. The organic electroluminescent element consists of a glass substrate (1), an anode (2), a hole transporting layer (10), an emitting layer (11), an electron transporting layer (12), and a cathode (3), which are sequentially laminated on top of the other. The emitting layer (11) is formed from a mixture composed of at least one species of the styryl compound represented by the general formula [I] below and a material with charge transporting capability.

Y—CH═CH—X   General formula [I]

(where X denotes an aryl group (such as phenyl group) which has a substituent group (such as cyano group and methyl group), and Y denotes a group having a skeleton of aminophenyl group or the like.)

A high-yield process for converting lignin into reformulated, partially oxygenated gasoline compositions of high quality is provided. The process is a two-stage catalytic reaction process that produces a reformulated, partially oxygenated gasoline product with a controlled amount of aromatics. In the first stage of the process, a lignin feed material is subjected to a base-catalyzed depolymerization reaction, followed by a selective hydrocracking reaction which utilizes a superacid catalyst to produce a high oxygen-content depolymerized lignin product mainly composed of alkylated phenols, alkylated alkoxyphenols, and alkylbenzenes. In the second stage of the process, the depolymerized lignin product is subjected to an exhaustive etherification reaction, optionally followed by a partial ring hydrogenation reaction, to produce a reformulated, partially oxygenated/etherified gasoline product, which includes a mixture of substituted phenyl/methyl ethers, cycloalkyl methyl ethers, C7-C10 alkylbenzenes, C6-C10 branched and multibranched paraffins, and alkylated and polyalkylated cycloalkanes.

A compound represented by Formula 1 below:

(R₁)_a—CB—[Ar]_n—CB—(R₂)_b  <Formula 1>

• • wherein CB denotes carborane, Ar is a substituted or unsubstituted phenylene group, and a detailed description of R₁, R₂, a, b, and n is provided in the detailed description. An organic light-emitting diode including an organic layer including the compound has high luminous efficiency.

A method is provided for processing a substrate including providing a processing gas comprising an organosilicon compound comprising a phenyl group to the processing chamber, and reacting the processing gas to deposit a low k silicon carbide barrier layer useful as a barrier layer in damascene or dual damascene applications with low k dielectric materials.

The present invention relates to a compound represented by Formula (1) and a polymer obtained using the compound:

wherein R¹ is phenyl which may have substituents, Q¹ is hydrogen, halogen, alkyl having 1 to 10 carbon atoms, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl or phenyl in which optional hydrogen may be replaced by halogen or alkyl having 1 to 5 carbon atoms,

and Q² is a group represented by Formula (2) wherein the code < represents a bonding point with silicon, l, m, n and p are independently 0, 1, 2 or 3, A¹ to A⁴ are independently a single bond, 1,4-cyclohexylene, 1,4-cyclohexenylene, a condensed ring group having 6 to 10 carbon atoms which is a divalent group, or 1,4-phenylene, Z⁰ to Z³ are independently a single bond, —CH═CR—, —C≡C—, —COO—, —OCO—, or alkylene having 1 to 20 carbon atoms, and Z⁴ is a single bond, —CH═CH—, —C≡C—, —COO—, —OCO—, or alkylene having 1 to 20 carbon atoms. And Y¹ in Formula (1) is the group defined in Claim 1.

The present invention provides a compound represented by the formula (I):

or a pharmacologically acceptable salt thereof, wherein Ar₁ represents an imidazolyl group that may be substituted with a C1-6 alkyl group, or the like, Ar₂ represents a phenyl group that may be substituted with a C1-6 alkoxy group, or the like, X₁ represents a double bond or the like, and Het represents an imidazolyl group that may be substituted with a C1-6 alkyl group, or the like, which is effective as a therapeutic or prophylactic agent for a disease caused by Aβ.

In one aspect, the invention relates to compounds, including phenylethynylbenzamide derivatives, cycloalkylethynylbenzamide derivatives, styrylbenzamide derivatives, 4-(3-phenyl-1,2,4-oxadiazol-5-yl)benzamide derivatives, 4-(pyridinylethynyl)benzamide derivatives, and N¹-phenylterephthalamide derivatives, which are useful as positive allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with glutamate dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

To provide a light-emitting element having high luminous efficiency and to provide a light-emitting device and an electronic device which consumes low power and is driven at low voltage, a carbazole derivative represented by the general formula (1) is provided. In the formula, α¹, α², α³, and α⁴ each represent an arylene group having less than or equal to 13 carbon atoms; Ar¹ and Ar² each represent an aryl group having less than or equal to 13 carbon atoms; R¹ represents any of a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, a substituted or unsubstituted phenyl group, and a substituted or unsubstituted biphenyl group; and R² represents any of an alkyl group having 1 to 6 carbon atoms, a substituted or unsubstituted phenyl group, and a substituted or unsubstituted biphenyl group. In addition, l, m, and n are each independently 0 or 1.

The present invention provides a cytokine production inhibitor containing as an active ingredient an aniline derivative of the formula (I) or a salt thereof:

[wherein A is CO or SO₂; Cy is an aryl group or a heterocyclic group; each of R¹ and R² which are independent of each other, is a halogen atom, a cyano group, a nitro group, an alkyl group which may be substituted, an alkenyl group which may be substituted, an alkynyl group which may be substituted, a cycloalkyl group which may be substituted, a cycloalkenyl group which may be substituted, an aryl group which may be substituted, a heterocyclic group which may be substituted, an amino group which may be substituted or a —B-Q group; R³ is a -M¹-M²-R⁵ group; R⁴ is a hydrogen atom or an alkyl group which may be substituted; x is an integer of from 0 to 5; y is an integer of from 0 to 4; and z is an integer of from 0 to 1].

The invention relates to compounds of structural formula (Ia):

or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof, wherein X₁, X₂, X₃, X₄, X₆, X₁₀, R₁, Y, Z, L, and n are defined herein. These compounds are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders.

A compound having the formula (I) or a pharmaceutically acceptable salt thereof where the variables are defined in the specification are useful in the treatment of sickle-cell anemia.

PCT No. PCT/JP97/01871 Sec. 371 Date Feb. 3, 1998 Sec. 102(e) Date Feb. 3, 1998 PCT Filed Jun. 2, 1997 PCT Pub. No. WO97/46601 PCT Pub. Date Dec. 11, 1997A curable liquid resin composition containing 100 parts by weight of the following (meth)acrylic liquid resin (A) and 1 to 1,000 parts by weight of a (meth)acrylic monomer (B) having an unsaturated double bond in its molecule and having a number average molecular weight of 1,000 or less, the (meth)acrylic liquid resin (A) being a liquid resin which is obtained by polymerizing monomers containing an alkyl (meth)acrylate monomer (a-1-1) of the formula (1),CH2 C(R1)COO-R2(1)wherein R1 is a hydrogen atom or CH3 and R2 is an alkyl group, and/or an alkylene glycol (meth)acrylate monomer (a-1-2) of the formula (2),CH2=C(R1)COO(CnH2nO)mR3(2)wherein R1 is a hydrogen atom or CH3, R3 is an alkyl group or a phenyl group, n is an integer of 1 to 3, and m is an integer of 3 to 25, and other polymerizable vinyl monomer (a-2), an average of molecular weights of all the monomers being 100 to 1,500, the liquid resin having a number average molecular weight of 10,000 to 200,000 and a viscosity of 1 to 10,000 poise (measured at 50 DEG C.), or a modified product of the above liquid resin, the curable liquid resin composition can form a film as a film-forming material or as a resin for an adhesive without using a solvent and give a cured film.

The invention relates to a thermal activation delayed fluorescent material with a general formula of the structure shown as the formula (I) or the formula (II). D is one of phenoxazinyl, phenothizainyl, 9,9-dimethyl acridine, 9-methyl phenazinyl, 9-phenyl phenazinyl, 4-phenoxazinyl-1-phenyl, 4-phenothizainyl-1-phenyl, 4-(9,9-dimethyl)acridinyl-1-phenyl, 4-(9-methyl)-phenazinyl-1-phenyl, 4-(9-phenyl)phenazinyl-1-phenyl and 3,5-bis-carbazolyl-1-phenyl. The invention further relates to an organic electroluminescent device which comprises a light-emitting layer, and luminescent dye of the light-emitting layer is the thermal activation delayed fluorescent material. The singlet state-triplet state energy gap (delta EST) of the thermal activation delayed fluorescent material is very small, triplet state excitors can be converted into singlet state excitors through inverse intersystem crossing (RIST) to emit light, and the efficiency and stability of an OLED device can be improved. The formula is shown in the description.

The preferred embodiments are directed to small molecule inhibitors that are cellular proliferation inhibitors and thus are useful as anticancer agents. The small molecules have the general formulas that include a phenylbenzimidazole core ring.

This invention provides a compound of the following formula:and the pharmaceutically acceptable salts thereof, wherein L is oxygen or sulfur; Y is a direct bond or C1-4 alkylidene; Q is C1-6 alkyl, C3-7 cycloalkyl, phenyl, naphthyl, heteroaryl or the like; R1 is hydrogen, C1-6 alkyl or the like; R2 is hydrogen, C1-4 alkyl, C(O)R5 wherein R5 is C1-22 alkyl or C2-22 alkenyl, halosubstituted C1-8 alkyl, halosubstituted C2-8alkenyl, -Y-C3-7 cycloalkyl, -Y-C3-7 cycloalkenyl, phenyl, naphthyl, heteroaryl or the like; X is halo, C1-4 alkyl, hydroxy, C1-4 alkoxy or the like; and n is 0, 1, 2 or 3, with the proviso that a group of formula -Y-Q is not methyl or ethyl when X is hydrogen; L is oxygen; R1 is hydrogen; and R2 is acetyl.This invention also provides a pharmaceutical composition useful for the treatment of a medical condition in which prostaglandins are implicated as pathogens.

The present invention is directed to a method of making a ligand which can be used to form an ansa-metallocene. Further, the present invention is directed to a method of making the ansa-metallocene. In both methods the process steps employed to form the ligand are conducted in the presence of tetrahydrofuran, a substituted tetrahydrofuran, tetrahydropyran, a substituted tetrahydropyran or ethylene glycol dimethyl ether.

An organic electroluminescence device of the present invention comprises a light emitting layer held between electrodes, the light emitting layer containing at least a host material and a dye or pigment. The light emitting layer further comprises an additive exhibiting an absorption edge of which energy level is higher than that of an absorption edge of the dye or pigment, but the difference of the energy levels being less than 120 kJ/mol, having no lone pair, and including at least two aromatic rings. The additive of the present invention is selected from a group consisting of phenyl-substituted anthracenes, naphthyl-substituted anthracenes, naphthyl-substituted naphthalenes, pyrenes, and a naphthacene derivatives.

Pre-impregnated composite material (prepreg) is provided that can be molded to form composite parts that have high levels of both strength and damage tolerance without causing any substantial negative impact upon the physical or chemical characteristics of the uncured prepreg or cured part. This is achieved by including in the matrix resin a substantial amount of a multifunctional aromatic epoxy resin that has at least one phenyl group that is meta-substituted.